

Mouse Anti-Prostein [A5]: MC0172

Intended Use: For Research Use Only

Description: PSA, prostate specific antigen, is the classic indicator for transformed pro-state tissue; however, in addition to being upregulated in prostate cancer, PSA is also upregulated in non-malignant conditions, such as benign prostatic hyperplasia. Prostein, also designated Prostate cancer-associated protein 6, is a prostate-specific, 553 amino acid transmembrane protein that is upregulated by androgens. It is considered a marker for prostate cells since it is expressed in all prostatic glandular cells as well as in normal and cancerous prostate tissues. Since it is able to elicit a tumor-directed cytotoxic T cell response, Prostein may be used as a target for the development of PSA- and T cell-based therapeutic strategies for prostate cancer.

Specifications

Clone: A5
Source: Mouse
Isotype: IgG2a/k
Reactivity: Human, mouse, rat
Localization: Membrane, cytoplasm
Formulation: Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN₃)
Storage: Store at 2°- 8°C
Applications: IHC, ELISA, ICC/IF, IP, WB
Package:

Description	Catalog No.	Size
Prostein Concentrated	MC0172	1 ml

IHC Procedure*

Positive Control Tissue: Prostate cancer, prostate tissue lysates, benign prostatic adenocarcinoma, prostate hyperplasia tissue, LnCaP cell lysates
Concentrated Dilution: 50-200
Pretreatment: Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
Incubation Time and Temp: 30-60 minutes @ RT
Detection: Refer to the detection system manual
* Result should be confirmed by an established diagnostic procedure.



FFPE human prostate tissue stained with anti-Prostein showing cytoplasmic and membrane staining of glandular cells.

References:

1. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA. Kristiansen I, et al. Int J Mol Sci. May 29;18(6), 2017.
2. Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study. Seipel AH et al. APMIS. 2016.

Doc. 100-MC0172
Rev. A